Global incidence of malignant brain and other central nervous system tumors by histology, 2003–2007

Background Previous reports have shown that overall incidence of malignant brain and other central nervous system (CNS) tumors varied significantly by country. The aim of this study was to estimate histology-specific incidence rates by global region and assess incidence variation by histology and age. Methods Using data from the Central Brain Tumor Registry of the United States (CBTRUS) and the International Agency for Research on Cancer's (IARC) Cancer Incidence in Five Continents X (including over 300 cancer registries), we calculated the age-adjusted incidence rates (AAIR) per 100000 person-years and 95% CIs for brain and other CNS tumors overall and by age groups and histology. Results There were significant differences in incidence by region. Overall incidence of malignant brain tumors per 100000 person-years in the US was 5.74 (95% CI = 5.71-5.78). Incidence was lowest in Southeast Asia (AAIR = 2.55, 95% CI = 2.44-2.66), India (AAIR = 2.85, 95% CI = 2.78-2.93), and East Asia (AAIR = 3.07, 95% CI = 3.02-3.12). Incidence was highest in Northern Europe (AAIR = 6.59, 95% CI = 6.52-6.66) and Canada (AAIR = 6.53, 95% CI = 6.41-6.66). Astrocytic tumors showed the broadest variation in incidence regionally across the globe. Conclusion Brain and other CNS tumors are a significant source of cancer-related morbidity and mortality worldwide. Regional differences in incidence may provide clues toward genetic or environmental causes as well as a foundation for broadening knowledge of their epidemiology. Gaining a comprehensive understanding of the epidemiology of malignant brain tumors globally is critical to researchers, public health officials, disease interest groups, and clinicians and contributes to collaborative efforts in future research.

[1]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[2]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[3]  Alexander R. Pico,et al.  Variants in the CDKN2B and RTEL1 regions are associated with high grade glioma susceptibility , 2009, Nature Genetics.

[4]  Damien C Weber,et al.  Epidemiology of glial and non-glial brain tumours in Europe. , 2012, European journal of cancer.

[5]  D. Louis WHO classification of tumours of the central nervous system , 2007 .

[6]  P. Black,et al.  Epidemiology of intracranial meningioma. , 2005, Neurosurgery.

[7]  J. Barnholtz-Sloan,et al.  The epidemiology of glioma in adults: a "state of the science" review. , 2014, Neuro-oncology.

[8]  S. Weiland,et al.  Global variation in the prevalence and severity of asthma symptoms: Phase Three of the International Study of Asthma and Allergies in Childhood (ISAAC) , 2009, Thorax.

[9]  Joshua C Denny,et al.  Assessing the accuracy of observer-reported ancestry in a biorepository linked to electronic medical records , 2010, Genetics in Medicine.

[10]  Ram C Tiwari,et al.  Efficient interval estimation for age-adjusted cancer rates , 2006, Statistical methods in medical research.

[11]  G. Gao,et al.  RTEL1 tagging SNPs and haplotypes were associated with glioma development , 2013, Diagnostic Pathology.

[12]  Melissa Bondy,et al.  Genome-wide association study identifies multiple susceptibility loci for glioma , 2022 .

[13]  Rebecca L. Siegel Mph,et al.  Cancer statistics, 2016 , 2016 .

[14]  Donald L. Miller,et al.  Cancer risks associated with external radiation from diagnostic imaging procedures , 2012, CA: a cancer journal for clinicians.

[15]  C. Mathers,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .

[16]  R. McLendon,et al.  Issues of Diagnostic Review in Brain Tumor Studies: From the Brain Tumor Epidemiology Consortium , 2008, Cancer Epidemiology Biomarkers & Prevention.

[17]  C. Muir,et al.  International Classification of Diseases for Oncology , 1990 .

[18]  Melissa Bondy,et al.  Genome-wide association study of glioma and meta-analysis , 2012, Human Genetics.

[19]  Martin J. Bent,et al.  Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective , 2010, Acta Neuropathologica.

[20]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[21]  Melissa Bondy,et al.  Genome-wide association study identifies five susceptibility loci for glioma , 2009, Nature Genetics.

[22]  H. Chiou,et al.  Comparative Brain and Central Nervous System Tumor Incidence and Survival between the United States and Taiwan Based on Population-Based Registry , 2016, Front. Public Health.

[23]  K. Strauch,et al.  Low penetrance susceptibility to glioma is caused by the TP53 variant rs78378222 , 2013, British Journal of Cancer.

[24]  B. Scheithauer,et al.  The New WHO Classification of Brain Tumours , 1993, Brain pathology.

[25]  C. Counsell,et al.  Incidence studies of primary and secondary intracranial tumors: A systematic review of their methodology and results , 1998, Journal of Neuro-Oncology.

[26]  Joseph Wiemels,et al.  Epidemiology and etiology of meningioma , 2010, Journal of Neuro-Oncology.

[27]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[28]  X. Su,et al.  Comprehensive study on associations between nine SNPs and glioma risk. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[29]  F. Bray,et al.  Cancers of the brain and CNS: global patterns and trends in incidence , 2016, Neuro-oncology.

[30]  I. Buchan,et al.  Environmental risk factors for cancers of the brain and nervous system: the use of ecological data to generate hypotheses , 2013, Occupational and Environmental Medicine.

[31]  M. Curado,et al.  Cancer registration data and quality indicators in low and middle income countries: their interpretation and potential use for the improvement of cancer care , 2009, Cancer Causes & Control.

[32]  Nathalie Jette,et al.  The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis. , 2015, Neuro-oncology.

[33]  Susan M. Chang,et al.  Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis. , 2013, Neuro-oncology.

[34]  Y. Mao,et al.  Fine mapping analysis of a region of 20q13.33 identified five independent susceptibility loci for glioma in a Chinese Han population. , 2012, Carcinogenesis.

[35]  Jill S. Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012 , 2015, Neuro-oncology.

[36]  G. Barger,et al.  Discrepancies in diagnoses of neuroepithelial neoplasms , 2000, Cancer.

[37]  G. Giles,et al.  Allergy and brain tumors in the INTERPHONE study: pooled results from Australia, Canada, France, Israel, and New Zealand , 2013, Cancer Causes & Control.

[38]  Hadley Wickham,et al.  ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .